Latest revenue
$105.4M
as of 2026-03-31
Latest net income
$-11.2M
as of 2026-03-31
Net margin
-10.6%
as of 2026-03-31
ActaClear Score
Computed from 5 years of SEC fundamentals + latest market data, ranked within Pharmaceutical Preparations (528 peers). 10 = best in industry, 5 = median, 0 = worst. Refreshed Jun 7, 2026.
Community sentiment
Where do you think ARQT is heading?
Price · 5Y
Live market
delayed ≤15 min- Market cap
- $2.65B
- Enterprise value
- $2.73B
- P/E (trailing)
- —
- Forward P/E
- —
- P/B
- 14.00×
- Dividend yield
- 0.0%
- 52-wk high
- $31.77
- 52-wk low
- $12.72
- Beta
- —
- Shares out
- 125.1M
5-year trend
What this company does
Part I Item 1. BUSINESS Overview We are a commercial-stage biopharmaceutical company focused on developing and commercializing treatments for dermatological diseases with high unmet medical needs. Our current portfolio is comprised of highly differentiated topical and systemic treatments with significant potential to treat immune-mediated dermatological diseases and conditions. We believe we have built a leading platform for dermatologic product development and commercialization. Our strategy is to focus on validated biological targets, and to use our drug development platform and deep dermatology expertise to develop and commercialize differentiated products that have the potential to…
AI summary unavailable — showing raw filing excerpt
Generated from ARQT's filing dated 2026-02-25
Key risks
Item 1A. RISK FACTORS This Annual Report on Form 10-K contains forward-looking information based on our current expectations. Because our business is subject to many risks and our actual results may differ materially from any forward-looking statements made by or on behalf of us, this section includes a discussion of important factors that could affect our business, operating results, financial condition, and the trading price of our common stock. This discussion should be read in conjunction with the other information in this Annual Report on Form 10-K, including our financial statements and the related notes and “Management’s Discussion and Analysis of Financial Condition and Results of…
AI summary unavailable — showing raw filing excerpt
Generated from ARQT's filing dated 2026-02-25
Profitability
Operating margin
-3.3%
95.0%Net margin
-4.3%
94.0%Return on equity
-10.2%
88.5%Return on assets
-3.7%
90.7%Leverage
Debt / equity
1.75×
43.9%Long-term debt / equity
0.69×
0.7%Debt / assets
63.6%
16.0%Earnings tracker
| Quarter | Revenue | YoY | Net income | YoY | Net margin |
|---|---|---|---|---|---|
Q1 2026 2026-03-31 | $105.4M | +65.1% | $-11.2M | +54.8% | -10.6% |
Q4 2025 2025-12-31 | $131.5M | +32.4% | $16.8M | +251.0% | 12.8% |
Q3 2025 2025-09-30 | $99.2M | +121.7% | $7.4M | +117.8% | 7.5% |
Q2 2025 2025-06-30 | $81.5M | +164.1% | $-15.5M | +70.3% | -19.1% |
Q1 2025 2025-03-31 | $63.8M | +196.0% | $-24.8M | +29.3% | -38.8% |
Q4 2024 2024-12-31 | $99.4M | — | $-11.1M | — | -11.2% |
Q3 2024 2024-09-30 | $44.8M | +451.9% | $-41.5M | +0.5% | -92.8% |
Q2 2024 2024-06-30 | $30.9M | +546.9% | $-52.3M | +26.3% | -169.6% |
Year-over-year change vs the same fiscal quarter one year prior. Revenue + net income sourced from SEC 10-Q / 10-K filings — no analyst-consensus dependency.
Industry trend
Pharmaceutical Preparations · SIC 2834
Your notes
Keep private notes on ARQT — thesis, target price, catalysts to watch.
Visible only to you. Never shared. Never used to train AI.
Insider activity
Insider buying
$34.6K
Insider selling
$17.0M
Net activity
−$17.0M
Distinct insiders
11
Open-market trades over the last 365 days.
Recent transactions
Source: SEC Form 4 filings. Officers, directors, and 10%+ owners must disclose share transactions within two business days. RSU grants and tax-withholding rows are excluded by default — compensation activity is not a trading signal.
Who owns ARQT
Institutional value
$1.01B
Total shares held
44.1M
Distinct holders
149
-127 vs prior
As of
2026-03-31
Prior: 2025-12-31
Filers with $100M+ AUM disclose holdings 45 days after quarter end.
Top institutional holders
| # | Manager | Shares | Value | QoQ change | Action |
|---|---|---|---|---|---|
| 1 | BlackRock, Inc. | 9.2M | $216.8M | +100.8K (+1.1%) | Added |
| 2 | JENNISON ASSOCIATES LLC | 5.0M | $117.3M | -1.8M (-26.3%) | Trimmed |
| 3 | VANGUARD CAPITAL MANAGEMENT LLC | 4.9M | $114.8M | — | New |
| 4 | UBS Group AG | 3.3M | $78.4M | +85.8K (+2.6%) | Added |
| 5 | FRANKLIN RESOURCES INC | 2.3M | $54.1M | +397.9K (+20.9%) | Added |
| 6 | VANGUARD PORTFOLIO MANAGEMENT LLC | 2.0M | $46.1M | — | New |
| 7 | Ensign Peak Advisors, Inc | 1.2M | $29.3M | -658.0K (-34.6%) | Trimmed |
| 8 | Candriam S.C.A. | 1.1M | $25.6M | -519.6K (-32.3%) | Trimmed |
| 9 | FEDERATED HERMES, INC. | 1.1M | $25.4M | +185.5K (+20.8%) | Added |
| 10 | Perpetual Ltd | 909.5K | $21.4M | -1.1K (-0.1%) | Trimmed |
| 11 | Nuveen, LLC | 902.1K | $21.3M | -480.0K (-34.7%) | Trimmed |
| 12 | BNP PARIBAS FINANCIAL MARKETS | 812.1K | $19.1M | +112.3K (+16.1%) | Added |
| 13 | VANGUARD FIDUCIARY TRUST CO | 771.8K | $18.2M | — | New |
| 14 | abrdn plc | 645.1K | $15.2M | +58.7K (+10.0%) | Added |
| 15 | FISHMAN JAY A LTD/MI | 566.7K | $13.4M | +2.1K (+0.4%) | Added |
| 16 | M&G PLC | 469.1K | $11.3M | — | New |
| 17 | DEUTSCHE BANK AG\ | 389.8K | $9.2M | -540.4K (-58.1%) | Trimmed |
| 18 | FIRST TRUST ADVISORS LP | 351.2K | $8.3M | -53.4K (-13.2%) | Trimmed |
| 19 | Penn Capital Management Company, LLC | 333.1K | $7.9M | — | New |
| 20 | Privium Fund Management B.V. | 321.0K | $7.6M | +15.0K (+4.9%) | Added |
Source: SEC Form 13F-HR. Positions aggregated across sub-managers within each firm. Options (puts/calls) excluded — common stock only.
Top questions investors are asking
Coming once ARQT's latest filing finishes processing.
Sign in to vote. Votes use 7-day half-life decay.
Sign in to tap. 7-day half-life decay.